Susan Brown
Hematology & Oncology · Niles, ILNPI 1003805375
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in IL, where the typical reported total is $2,365.
Across 137 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$294
- Genentech USA, Inc.$196
- Novartis$181
- Takeda Pharmaceuticals U.S.A., Inc.$159
- Merck$141
- E.r. Squibb & Sons, L.L.C.$131
- plus $1K from 31 others
Across 137 payments — averaging $960.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$101K
- Eli Lilly$21K
- Pfizer$9K
What the payments were for
- Food & beverage$2,530100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 13 | $294 |
| Genentech USA, Inc. | 11 | $196 |
| Novartis | 11 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $159 |
| Merck | 9 | $141 |
| E.r. Squibb & Sons, L.L.C. | 11 | $131 |
| Tesaro, Inc. | 3 | $122 |
| Sanofi | 6 | $98 |
| Pfizer | 9 | $96 |
| Octapharma USA, Inc. | 1 | $91 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $91 |
| Johnson & Johnson(2 entities) | 5 | $87 |
| Bristol Myers Squibb | 4 | $83 |
| Incyte Corporation | 4 | $73 |
| Astellas Pharma US Inc | 4 | $64 |
| Daiichi Sankyo Inc. | 3 | $62 |
| AbbVie | 3 | $51 |
| Lilly USA, LLC | 3 | $51 |
| Bayer | 3 | $49 |
| Seagen Inc. | 3 | $47 |
| AstraZeneca | 3 | $45 |
| Taiho Oncology, Inc. | 2 | $41 |
| EMD Serono, Inc. | 3 | $38 |
| Eisai Inc. | 2 | $32 |
| Array Biopharma Inc | 1 | $23 |
| Exelixis Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $13 |
| Verastem, Inc. | 1 | $12 |
How this compares
$2,542 in reported general payments places this provider in the 50th percentile of 580 hematology & oncology providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisinopril | 12 | $70 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Niles
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
- Gary KayElk Grove Village$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.